General Information of Drug Combination (ID: DCUQUC3)

Drug Combination Name
Mycophenolate mofetil Cyclosporin A
Indication
Disease Entry Status REF
Adenosine Deaminase Deficiency Phase 1 [1]
Component Drugs Mycophenolate mofetil   DMPQAGE Cyclosporin A   DMUYKBZ
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Mycophenolate mofetil
Disease Entry ICD 11 Status REF
Hepatosplenic T-cell lymphoma N.A. Approved [2]
Interstitial cystitis GC00.3 Approved [2]
Large granular lymphocytic leukemia 2A90.1 Approved [2]
Lupus nephritis 4A40.0Y Approved [2]
MALT lymphoma N.A. Approved [2]
Myeloid leukaemia 2B33.1 Approved [2]
Myeloproliferative neoplasm 2A20 Approved [2]
Nodal marginal zone lymphoma 2A85.0 Approved [2]
Organ transplant rejection NE84 Approved [3]
Primary cutaneous peripheral T-cell lymphoma not otherwise specified N.A. Approved [2]
Recurrent adult burkitt lymphoma 2A85.6 Approved [2]
Small intestine lymphoma N.A. Approved [2]
Splenic marginal zone lymphoma N.A. Approved [2]
Systemic lupus erythematosus 4A40.0 Approved [2]
Testicular lymphoma N.A. Approved [2]
Pemphigus vulgaris EB40 Phase 3 [3]
Classic Hodgkin lymphoma N.A. Investigative [2]
Immune System disease 4A01-4B41 Investigative [4]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [5]
Mycophenolate mofetil Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Prostaglandin E2 receptor EP2 (PTGER2) TT1ZAVI PE2R2_HUMAN Modulator [4]
Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2) TTTB4UP IMDH2_HUMAN Inhibitor [16]
------------------------------------------------------------------------------------
Mycophenolate mofetil Interacts with 5 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [17]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [18]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [18]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [17]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [17]
------------------------------------------------------------------------------------
Mycophenolate mofetil Interacts with 8 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [19]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [20]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [19]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [19]
UDP-glucuronosyltransferase 2B7 (UGT2B7) DEB3CV1 UD2B7_HUMAN Metabolism [19]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Metabolism [21]
UDP-glucuronosyltransferase 1A6 (UGT1A6) DESD26P UD16_HUMAN Metabolism [20]
UDP-glucuronosyltransferase 1A10 (UGT1A10) DEL5N6Y UD110_HUMAN Metabolism [22]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DME(s)
Indication(s) of Cyclosporin A
Disease Entry ICD 11 Status REF
Adult acute monocytic leukemia N.A. Approved [6]
Bronchiolitis obliterans syndrome N.A. Approved [7]
Large granular lymphocytic leukemia 2A90.1 Approved [8]
Leukemia N.A. Approved [9]
Lupus nephritis 4A40.0Y Approved [10]
Myeloid leukaemia 2B33.1 Approved [11]
Psoriasis EA90 Approved [12]
Xerophthalmia 5B55.Y Approved [13]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 1 [14]
Corneal disease 9A78.Z Investigative [15]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Kidney Transplantation DC66M1D N. A. Phase 4 [23]
Liver Transplantation DCNKNWM N. A. Phase 4 [24]
Dyskeratosis Congenita DCZHK3W N. A. Phase 2 [25]
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities DCXMKNG N. A. Phase 2 [26]
Accelerated Phase Chronic Myelogenous Leukemia DC6CQ1B N. A. Phase 1 [27]
Acute Myeloid Leukemia/Transient Myeloproliferative Disorder DCMN5XC N. A. Phase 1 [28]
Kidney Dysfunction DC6PKR5 N. A. Phase 1 [29]
Adult Acute Myeloid Leukemia in Remission DC1564L N. A. Phase 1 [30]
Recurrent Renal Cell Cancer DCUTAIB N. A. Phase 1 [31]
------------------------------------------------------------------------------------
⏷ Show the Full List of 9 DrugCom(s)

References

1 ClinicalTrials.gov (NCT00008450) Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant
2 Mycophenolate mofetil FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6831).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 341).
5 High-Throughput Screening and Identification of Potent Broad-Spectrum Inhibitors of Coronaviruses. J Virol. 2019 May 29;93(12). pii: e00023-19.
6 Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia. Haematologica. 2023 Jan 1;108(1):61-68.
7 Bronchiolitis obliterans syndrome is associated with increased senescent lymphocytes in the small airways. J Heart Lung Transplant. 2021 Feb;40(2):108-119.
8 Rituximab for rheumatoid arthritis-associated large granular lymphocytic leukemia, a retrospective case series. Semin Arthritis Rheum. 2020 Oct;50(5):1109-1113.
9 Cyclosporin A protects JEG-3 cells against oxidative stress-induced apoptosis by inhibiting the p53 and JNK/p38 signaling pathways. Reprod Biol Endocrinol. 2020 Oct 12;18(1):100.
10 Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational study. Front Immunol. 2023 Mar 8;14:1062919.
11 Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2024 Feb;11(2):e127-e135.
12 Pustular psoriasis. Cutis. 1993 Jan;51(1):29-32.
13 Cyclosporin A (CyA) in primary Sj?gren's syndrome: a double blind study. Ann Rheum Dis. 1986 Sep;45(9):732-5.
14 Why Choose Cyclosporin A as First-line Therapy in COVID-19 Pneumonia. Reumatol Clin. 2020 Apr 16;S1699-258X(20)30044-9.
15 Anti-inflammatory therapy of dry eye. Ocul Surf. 2003 Jan;1(1):31-6.
16 Clinical pipeline report, company report or official report of Roche (2009).
17 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
18 Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64.
19 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
20 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
21 The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
22 [Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. 2001;22(7):331-7.
23 ClinicalTrials.gov (NCT00087581) Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation
24 ClinicalTrials.gov (NCT00118742) Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant
25 ClinicalTrials.gov (NCT01659606) Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
26 ClinicalTrials.gov (NCT00040846) Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
27 ClinicalTrials.gov (NCT00005799) Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
28 ClinicalTrials.gov (NCT00014235) Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
29 ClinicalTrials.gov (NCT00420537) Shift to Everolimus (RAD) Kidney Sparing Study
30 ClinicalTrials.gov (NCT00008177) Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
31 ClinicalTrials.gov (NCT00005851) Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer